CSN Login
Members Online: 3

You are here

Immunotherapy clinical trial!

Posts: 39
Joined: Oct 2017

I am starting a new thread because my dad is no longer going to be receiving docetaxel chemotherapy. His Foundation One genome testing returned this week. It showed ATM mutations, and he was referred to an immunotherapy clinical trial--a phase 2 trial where he will be receiving the trial drugs and not a placebo, to begin in two weeks. It will continue as long as there is clinical benefit (and discontinued if there is no clinical benefit).

The trial is testing the treatment of ATM mutated metastatic prostate cancer with avelumab (immunotherapy) and talazoparib (PARP inhibitor). Avelumab will be given via infusion twice monthly, and talazoparib is a daily pill. I can't seem to find much information for either drug in the treatment of prostate cancer, so would be grateful if any of you have seen anything or have any personal experience with either drug or drugs in their classes.

I will be happy to update throughout this process--here's hopin'!

VascodaGama's picture
Posts: 2941
Joined: Nov 2010


I share with you the desire for something good to happen. I wonder the name of the trial your dad will be doing.

These therapies involving Mabs in prostate cancer is quite new. There have been some trials since 2011 but only now they managed a consensual plan in treatments with the intent at cure. This is where the genetic test got its potential. It stratifies patients for a more targeted therapy. In your dad’s case, they found certain genes that are associated with ATM mutations linked to or provoking cancer. Findings of this type have been under investigation in breast cancer for already many years, which is a similar illness to prostate cancer (these share the same genes). Your dad’s clinical trial involve the work of two drugs, being the Talazoparib the monoclonal (the inhibitor) and the Avelumab the facilitator for the killing by the immune system.

The whole plan is to avoid that the protein PD-L1 created by the cancer gets together with the immune protein PD-1 which is a survival switch in all our cells. This switch must be turned off to let the cancerous cell to die.
We have discussed here before on Mabs but unfortunately all the exchanged superb opinions have been lost in the last outage of the forum (together with your initial thread). Mabs got worldwide attention since the last Nobel Prize on medicine (2018) given to Dr. James Allison and Dr. Tasuku Honjo for their discovery of cancer therapy by inhibition of negative immune regulation.

I hope the trial is a success and manages to eliminate the bandit for good.

For those interested in knowing your dad’s story, they can check it in this link;


Here is an article on the successful of Monoclonal antibodies as a therapeutic approach in cancer;


Here is a link to clinical trials using Avelumab;



Best wishes,



Posts: 39
Joined: Oct 2017

Your explanation was certainly easier to read than the many studies about these drugs on the internet!

I have been occasionally speaking to Bryce Olson with Sequence Me— he had a similar diagnosis, received immunotherapy for his mutation, and has been thriving and advocating for genome sequence testing for patients ever since. He may take a look at my dad’s genome report and be able to tell me more. I will keep updating here as I learn more!

Subscribe to Comments for "Immunotherapy clinical trial!"